News
-
-
-
COMMUNIQUÉ DE PRESSE
Condition of minimum acceptance in Zentiva’s Voluntary Public Purchase Offer waived – Acceptance Period remains unchanged and ends on 21 November 2024 at 24:00 CET
Zentiva AG waives minimum acceptance condition in APONTIS PHARMA purchase offer, maintaining original timeline. Significant shareholder acceptance received -
-
-
COMMUNIQUÉ DE PRESSE
APONTIS PHARMA shareholders can tender their shares from today – Offer Document published
Zentiva AG, a subsidiary of Zentiva Pharma, launches a voluntary public purchase offer for APONTIS PHARMA shares at EUR 10.00 each, representing a 52.9% premium. Management supports the offer -
-
-
COMMUNIQUÉ DE PRESSE
Zentiva announces voluntary public purchase offer for APONTIS PHARMA – Investment Agreement signed
Zentiva announces voluntary public purchase offer for APONTIS PHARMA with a 52.9% premium over the closing share price on 15 October 2024. Zentiva to acquire approx. 37.5% stake through share sale and purchase agreement with main shareholder
